Fig. 4: Eliglustat combined with ZA reduces MM bone disease with greater effect than either agent alone.

a Schematic illustrating the timeline and experimental design of eliglustat and ZA impact on bone measurements in 8-week-old C57BL/KaLwRijHsd 5TGM1-GFP MM-bearing male mice. b Representative images of micro-CT reconstruction of proximal tibiae from each group, including naive control (Ctr, n = 6 biologically independent animals), MM mice (MM, n = 7 biologically independent animals), MM mice with eliglustat chow (for 19 days) (MM + Elig, n = 7 biologically independent animals), MM mice with single dose ZA injection (0.01 mg/kg, MM + ZA, n = 7 biologically independent animals), or MM mice with single dose ZA injection (0.01 mg/kg), and eliglustat chow (for 19 days) (MM + ZA + Elig, n = 7 biologically independent animals). c–h Dot plots of BV/TV, BS, BS/BV, Tb.N, Conn.D, and Tb.Sp from each group (Ctr, n = 6; MM, n = 7; MM + Elig, n = 7; MM + ZA, n = 7; MM + ZA + Elig, n = 7 biologically independent animals). i Representative reconstruction images of proximal cortical bone from each group. j Bone lesions (holes) on the cortical bones from each mouse were counted (Ctr, n = 6; MM, n = 7; MM + Elig, n = 7; MM + ZA, n = 7; MM + ZA + Elig, n = 7 biologically independent animals). k Representative TRAP/0.2% methyl green stained tibial sections showing red OCs on the endocortical bone surface from each group. The result is representative of two independent experiments. l–n Bone histomorphometry parameters including Oc.S/BS, N.Oc/T.Ar, and N.Oc/B.Pm (Ctr, n = 6; MM, n = 7; MM + Elig, n = 7; MM + ZA, n = 7; MM + ZA + Elig, n = 7 biologically independent animals). Data are presented as mean values ± SEM. Exact p-values are depicted in the figure. Statistical analysis was performed using One-way ANOVA for c–h and l–n, and two-tailed t-test for j. Source data are provided as a Source Data file.